Introduction: The applicability of "Rubidium Chloride, Rb from Generator" radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology.
Experimental: A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated.
Results And Discussions: The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which Rb-chloride accumulates in the vascular phase but does not linger further.